Abstract:Systemic lupus erythematosus (SLE) is a chronic and often progressive autoimmune disorder marked clinically by a variable constellation of symptoms including fatigue, rash, joint pains, and kidney damage. The lungs, heart, gastrointestinal system, and brain can also be impacted, and individuals with lupus are at higher risk for atherosclerosis, thrombosis, thyroid disease, and other disorders associated with chronic inflammation . Autoimmune diseases are marked by erroneous immune responses in which the target of the immune response is a "self"-antigen, or autoantigen, driven by the development of antigen-specific B or T cells that have overcome the normal systems of self-tolerance built into the development of B and T cells. SLE is specifically characterized by the production of autoantibodies against nucleic acids and their binding proteins, including anti-double stranded DNA, anti-Smith (an RNA binding protein), and many others . These antibodies bind their nuclear-derived antigens to form immune complexes that cause injury and scarring through direct deposition in tissues and activation of innate immune cells . In over 50% of SLE patients, immune complex aggregation in the kidneys drives intrarenal inflammation and injury and leads to lupus nephritis, a progressive destruction of the glomeruli that is one of the most common causes of lupus-related death . To counter this pathology increasing attention has turned to developing approaches to reduce the development and continued generation of such autoantibodies. In particular, the molecular and cellular events that lead to long term, continuous activation of such autoimmune responses have become the focus of new therapeutic strategies to limit renal and other pathologies in lupus patients. The focus of this review is to consider how the innate immune system is involved in the development and progression of lupus nephritis and how a novel approach to inhibit innate immune activation by neutralizing the activators of this response, called Damage Associated Molecular Patterns, may represent a promising approach to treat this and other autoimmune disorders.

A Disintegrin and metalloproteinase carves T cell abnormalities and pathogenesis in systemic lupus erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Immunological pathogenesis and treatment of systemic lupus erythematosus

Post-translational Modifications in T Cells in Systemic Erythematosus Lupus

Aberrant CD200/CD200R1 Expression and Function in Systemic Lupus Erythematosus Contributes to Abnormal T-cell Responsiveness and Dendritic Cell Activity

Long Non-Coding RNAs in Systemic Lupus Erythematosus: New Insights into Disease Pathogenesis and Diagnosis.

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus

A Comprehensive Review of Immune-Mediated Dermatopathology in Systemic Lupus Erythematosus.

Immunopathogenesis of systemic lupus erythematosus: An update

E3 ligase FBXW7 aggravates TMPD-induced systemic lupus erythematosus by promoting cell apoptosis

Epigenetic Dysregulation in the Pathogenesis of Systemic Lupus Erythematosus

Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus

Targeting DAMPs with nucleic acid scavengers to treat lupus

Dendritic Cells in Systemic Lupus Erythematosus: from Pathogenic Players to Therapeutic Tools.

ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-β1

Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Unveiling the Nexus: Decoding Interactions Between Regulated Cell Death and Systemic Lupus Erythematosus Pathogenesis for Innovative Therapeutic Avenues

Aberrant Non-Coding RNA Expression in Patients with Systemic Lupus Erythematosus: Consequences for Immune Dysfunctions and Tissue Damage

Precision medicine in systemic lupus erythematosus

Aberrant B-Cell Activation in Systemic Lupus Erythematosus.